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Abstract
Background: Previous studies reported that Atorvastatin (ATOR) can improve the efficacy of Mesenchymal stem
cells (MSCs) transplantation after acute myocardial infarction (AMI). However, the results of those studies were
inconsistent. To clarify the beneficial effects of atorvastatin added to the cell therapy with MSCs in animal model of
acute myocardial infarction (AMI), we performed a systematic review and meta-analysis of case–control studies.
Methods: Searches were performed using the PubMed database, the Excerpta Medica Database (Embase), the
Science Citation Index, the China National Knowledge Information database, the Wanfang database, and the
Chinese Scientific and Technological Journal Database (VIP database). The search term included “Atorvastatin
(or Ator)”, “Mesenchymal Stem Cells (or Mesenchymal Stem Cell or MSC or MSCs)” and “Acute Myocardial Infarction
(or Myocardial Infarction or AMI or MI)”. The endpoints were the left ventricular ejection fraction (LVEF) in animal
model with AMI.
Results: In total, 5 studies were included in the meta-analysis. Pooled analysis indicated a significant LVEF difference at
4 weeks follow-up between MSCs + ATOR combine group and MSCs alone group (95 % CI, 9.09–13.62 %; P < 0.01) with
heterogeneity (P = 0.28; P >0.05) and inconsistency (I2: 22 %).
Conclusions: Atorvastatin can enhance the existing effects of MSCs transplantation, and this combinational therapy is
a superior cell/pharmacological therapeutic approach that merits future preclinical and clinical studies.
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Background
Acute myocardial infarction (AMI) is the leading cause
of death among people in industrialized nations [1]. Al-
though early revascularization can save part of ischemic
myocardium, necrotic myocardial cells, which cannot re-
generate, will gradually be replaced by scar tissue, lead-
ing to ventricular remodeling and heart failure, and thus
seriously affect the survival rate and quality of life of sur-
vivors [2]. Despite the rapid development of therapeutic
techniques and ideas, the treatments of heart failure sec-
ondary to AMI are still very limited, among which stem
cell transplantation is one of the most promising [3].
Due to no strong differentiation of immune rejection
and easy to get, the bone marrow-derived mesenchymal
stem cells (MSCs) is one of the best sources of trans-
planted cells. Therefore, MSCs have been widely utilized
as a result of their plasticity, availability, and lack of im-
munological rejection or ethical issues [4]. However,
many studies have demonstrated the poor survival and
retention of transplanted cells in vivo, whether this is
due to properties of the cells themselves, the extremely
hostile microenvironment in the per infarct region, or a
combination of both [5]. For these reasons the focus has
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been on efforts to improve the tolerance of stem cells to
the adverse microenvironment, which would hopefully
lead to the development of a clinical approach to im-
prove stem cell survival and tissue repair capacity [6].
Recent studies have demonstrated that combined therapy
with MSCs and atorvastatin (ATOR), a blood cholesterol-
lowering agent, produces synergistic beneficial effects in the
treatment of AMI [7]. However, the number of experimen-
tal animals in most of studies selected is limited. In
addition, many large animal studies in AMI and ischaemic
cardiomyopathy have been conflicting outcomes. We
hypothesize that meta-analysis of these experimental data
might be helpful to design future clinical studies similarly
to the meta-analysis of human cardiac stem cell trials.
We performed a systematic overview of the pertinent
literature including a quantitative meta-analysis to assess
the effects of stem cell transplantation in animals with
acute myocardial infarction. Combined MSCs therapy
and pharmacotherapy is one of these proof-in-principle
approaches.
Fig. 1 Flowchart of enrolled studies on cell therapy in animals with acute MI
Table 1 Characteristics of studies included in the Meta-Analysis
Author (year) Language Type of animal Number of cells Atorvastatin treatment Route of delivery Timing of cell therapy after MI
Zhang Q et al.
(2014) [16]
English Rat 5 × 106cells/animal 10 mg/kg/day Intramuscularly injection 4 weeks
Qu Z et al.
(2013) [17]
English Rabbit 4 × 107cells/50uL 1.5 mg/kg/day Intramuscularly injection 4 weeks
Song L et al.
(2013) [18]
English Swine 3 × 107cells/animal 0.25 mg/kg/day Intramuscularly injection 4 weeks
Cai A et al.
(2011) [19]
English Rat 1 × 106cells /100uL 10 mg/kg/day Intramuscularly injection 4 weeks
Yang YJ et al.
(2008) [20]
English Swine 3 × 107cells/animal 0.25 mg/kg/day Intramuscularly injection 4 weeks
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Methods
Search strategy
The following databases were searched in Dec 2014:
PubMed database, the Excerpta Medica Database
(Embase), the Science Citation Index, the China National
Knowledge Information database, the Wanfang database,
and the Chinese Scientific and Technological Journal
Database (VIP database).
For the association of ATOR, Mesenchymal Stem Cells
and Acute Myocardial Infarction, the following search
term were used in searching the previous database:
“Atorvastatin (or Ator)”, “Mesenchymal Stem Cells (or
Mesenchymal Stem Cell or MSC or MSCs)” and “Acute
Myocardial Infarction (or Myocardial Infarction or AMI
or MI)”. No language is limited. In addition, the refer-
ences of retrieved articles were also screened to find the
related papers. In addition, we performed manual
searches by scanning the reference lists of the selected
articles to locate additional papers related to the topic.
Study selection
Two investigators independently reviewed all studies
and extracted the data using a standard information ex-
traction and reached consensus on all items. Only those
articles that investigated the effect of ATOR combined
with mesenchymal stem cell transplantation on cardiac
function in animals with acute myocardial infarction
were included. Reviews, editorials, comments, reports
from scientific sessions and discussions were excluded.
We obtained the full text of articles that were identified
as either relevant or possibly relevant, based on their ti-
tles and abstracts.
Quality assessment and data extraction
The quality of studies was independently assessed by two
reviewers using a risk of bias assessment by van der Spoel
TI’s studies [8]: including randomization (yes/no), ad-
equate allocation (y/n), adequate method of randomization
(y/n), blinding of the operator (y/n), and blinding of the
functional analysis (y/n). The following information was
extracted from the complete manuscripts of the qualified
studies: basal characteristics of the study, the left ventricu-
lar ejection fraction (LVEF).
Statistical analysis
Our primary outcome was difference in mean LVEF
(reported in %) at follow-up between mesenchymal stem
cells transplantation group (MSCs group) and mesenchy-
mal stem cells treated with ATOR transplantation group
(MSCs + ATOR group). In case of multiple measurements
over time, data measured at the longest duration of
follow-up were used for analysis. A random-effect model
was applied. Continuous variables were reported as
weighted mean differences (WMD) with 95 % confidence
intervals (CI) between the cell-treated animals and control
groups. In case of data, the pooled estimate of effect was
presented as odds ratio (OR) with 95 % CI [9]. Inconsist-
ency was estimated by using the I2 statistic; values of 25,
50, and 75 % were considered low, moderate, and high in-
consistency, respectively [10]. Sensitivity analysis was also
performed to test the robustness of the results by exclud-
ing a study one by one. All analyses were performed with
Review Manager version 5 (The Nordic Cochrane Center,
København, Denmark) and IBM SPSS Statistics 19 (SPSS,
Chicago, IL, USA).
Table 2 Methodological quality of the included studies
Study RCT Adequate allocation Method of randomization described Operator blinded Analyst blinded
Zhang Q et al. (2014) [16] Y N N N N
Qu Z et al. (2013) [17] Y N N N N
Song L et al. (2013) [18] Y N N N N
Cai A et al. (2011) [19] Y N N N N
Yang YJ et al. (2008) [20] Y N N N N
RCT Randomized trial, Y Yes, N No
Table 3 Comparisons of cardiac function measured by echocardiography and hemodynamic examination in animal model of acute
myocardial infarction
Study Type of animal Control LVEF (%) Number MSCs LVEF (%) n Ator + MSCs LVEF (%) Number
Zhang Q et al. (2014) [16] Rat 48.1 ± 5.2 10 51.9 ± 2.4 10 65.3 ± 5.3 10
Qu Z et al. (2013) [17] Rabbit 48.67 8 59.14 9 67.32 9
Song L et al. (2013) [18] Swine 43.16 ± 8.02 6 48.75 ± 12.64 6 49.76 ± 12.09 6
Cai A et al. (2011) [19] Rat 44.63 ± 3.22 8 46.17 ± 2.03 7 56.78 ± 3.66 7
Yang YJ et al. (2008) [20] Swine 42.0 ± 7.1 6 41.3 ± 8.8 6 49.7 ± 10.4 7
LVEF (%) The left ventricular ejection fraction, (mean ± SD)
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Results
Search results
Totally forty-seven references were retrieved. Among
them, twenty were repetitive literatures in other data-
bases; eight literatures were excluded because they are
reviews, editorials, and or comments. In the end, five
case–control studies were included in the meta-analysis.
Figure 1 showed the flow diagram of studies selection.
The quality of studies
The five studies all established an AMI animal model by
performing thoracotomy and ligating the left descending
coronary artery, and then randomly divided them into
three groups: one group of AMI control group, one
group of MSC transplantation group, and the third
group conducted a joint ATOR and MSC transplant-
ation group. Table 1 lists the eligible studies which in-
cluded in as well as their main characteristics. Finally,
within the four weeks after transplantation, five studies
examined the left ventricular ejection fraction (LVEF) by
echocardiography. Table 2 show the methodological
quality of the enrolled studies. All studies reported the
method of randomization, but did not indicate whether
blinded analysis of LVEF. Table 3 shows the comparisons
of cardiac function measured by echocardiography and
hemodynamic examination in animal model of acute
myocardial infarction of the enrolled studies.
Meta-analysis
Within the four weeks after transplantation, five studies
examined LVEF, including thirty-eight cases in AMI con-
trol group, thirty-eight cases of MSC transplantation
group, and thirty-nine cases which conducted a joint
ATOR and MSC transplantation. Firstly, comparing
MSCs group and control group, it has been found a
LVEF difference of 2.30 % at follow-up after MSCs group
vs control (95 % CI, 0.25–4.36 %; P > 0.01) with incon-
sistency (I2: 0 %; Fig. 2), implying that there is no signifi-
cant difference between MSCs group and control group.
As shown in Fig. 3, pooled analysis showed a LVEF
difference of 13.16 % at follow-up after MSCs + ATOR
group vs. control (95 % CI, 10.55–15.78 %; P < 0.01)
with heterogeneity (P = 0.12; P > 0.05) and inconsistency
(I2: 48 %). The results suggested that, compared with
control, MSCs + ATOR contributes more to restoring
myocardial infarction cardiac function. As shown in
Fig. 4, pooled analysis showed a LVEF difference of
11.35 % at follow-up after MSCs + ATOR group vs.
MSCs group (95 % CI, 9.09–13.62 %; P < 0.01) with het-
erogeneity (P = 0.28; P > 0.05) and inconsistency (I2:
22 %). The results suggested that, compared with MSCs
transplantation alone, MSCs + ATOR contributes more
to restoring myocardial infarction cardiac function.
In addition, Sensitivity analysis demonstrated that the
result is same as before, indicated that the pooled meta-
analysis results is very robust. The funnel plot for LVEF
suggests a lack of publication bias as values were evenly
distributed around the overall estimate (Fig. 5).
Discussion
Although stem cells are studied clinically for cardiac re-
pair, its effects are still controversial [11]. Some studies
have shown that most stem cells were lost within 24 h
of transplantation, only 15 % survived for 12 weeks. The
quick loss after transplantation is mainly due to cell leak
age out of the myocardium or wash-out through the vas-
cular system [9]. Therefore, protection of graft cells from
acute death in ischemic myocardium is important for
Fig. 2 Forest plot showing the impact of MSCs therapy on LVEF improvement compared with controls
Fig. 3 Forest plot showing the impact of MSCs + Ator therapy on LVEF improvement compared with controls
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clinical applications. Common statins include prava-
statin, lovastatin, simvastatin and atorvastatin, which
were used agents in patients with coronary heart disease
owing to their superior ability to reduce blood choles-
terols [12]. Previous studies showed that different types
of statins play different roles in the induction of apop-
tosis of MSC. Lovastatin and atorvastatin have protective
effect [13], while simvastatin can promote apoptosis
[14]. The properties of Ator are well predicted to offer
improvement of the microenvironment for implanted
stem cells [15]. Among them most articles have explored
the combination of atorvastatin and MSC to treat myo-
cardial infarction.
The current analysis comprises data of five published
studies involving animals with AMI, which treated with
mesenchymal stem cells or Atorstatin +MSCs [16–20].
We first analyzed the therapy of AMI by MSCs trans-
plantation alone. However, it was found compared with
the control group, the recovery of ventricular function is
limited after transplantation, which might be related to
insufficient MSC’s survival rate. Subsequently, we ana-
lyzed the transplantation of ATOR combined with MSC,
it showed compared with both the control group and
MSC group, the ventricular function was significantly
improved as reflected by the magnified restoration of
the enlarged LVEF in AMI. The study showed the
therapeutic effect of the transplantation of ATOR+ MSC
is better than sole MSCs transplantation, which contrib-
utes to further clinical application of MSCs. Our data have
demonstrated that atorvastatin enhanced MSCs-induced
improvement of ischemic cardiac dysfunction, as reflected
by the magnified restoration of the enlarged LVEF in
AMI. This is to say, Ator can exert protective effects on
the myocardium undergoing infarction and reperfusion
injury in conjunction with MSC transplantation.
Limitations of this paper are in the following aspects:
1) the sample size is still relatively small, only including
approximately 80 animals of different species. It is hoped
that more researches can be incorporated; 2) the study
failed to analyze the appropriate dose of the drug. Dur-
ing transplantation, different studies chose a different
dose, but how much dose is the optimal needs further
study. 3) The study didn’t cover the mechanism of Ator.
This study researched the impact of Ator to the therapy
of AMI, but failed to provide data analysis of the causes
of the impact, for example, whether it is anti-apoptotic,
pro-differentiation, etc., which needs further study. 4)
Other statins may also have a similar effect, which is yet
to be explored. 5) D’Ascenzo F’s study shows that remote
ischaemic preconditioning (RIPC) can reduce the inci-
dence of periprocedural myocardial infarction (PMI) fol-
lowing percutaneous coronary intervention (PCI),
especially when performed in the lower limb and for pa-
tients with multivessel disease and complex lesions [21].
During the “ATOR +MSC” transplantation process,
RIPC may have a synergistic effect, which needs to be
further studied.
To the best of our knowledge, this is the first system-
atic review and meta-analysis in large animal models to
evaluate the effect of cell therapy in ischaemic heart dis-
ease. This analysis showed that large animal models are
valid to predict outcome of clinical trials. More-over, the
results showed that cardiac cell therapy is safe, led to an
improved LVEF, and revealed important clues for design-
ing (pre-) clinical trials.
The reported benefits of stem cell therapy for cardiac
function in clinical trials have been only modest. One of
the unresolved issues is the rather rapid disappearance
of cells after a few days, which is accompanied by the
lack of any demonstrable regenerative effect.
Fig. 4 Forest plot showing the impact of MSCs + Ator therapy on LVEF improvement compared with that of MSCs therapy
Fig. 5 Funnel plot for LVEF improvement between MSCs + ATOR
group and MSCs group. No evidence for publication bias was found.
SE, standard error; MD, mean difference
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Conclusions
Atorvastatin can enhance the existing effects of MSCs
transplantation, and this combinational therapy is a su-
perior cell/pharmacological therapeutic approach that
merits future preclinical and clinical studies.
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